Keith Michael Andrus Cardiac Award supports investigators studying cardiac involvement in Friedreich’s ataxia to improve understanding of associated cardiomyopathy and advance treatments.
Funder: Friedreich's Ataxia Research Alliance
Due Dates: February 15, 2027 (Letter of Intent) | April 15, 2027 (Application)
Funding Amounts: Up to $125,000 USD per year for one or two years; up to one award annually
Summary: Supports research advancing understanding and/or treatment of cardiac involvement in Friedreich’s ataxia.
Key Information: A competitive Letter of Intent review determines invitations to submit full applications.
The Keith Michael Andrus Cardiac Award honors Keith’s legacy by supporting research on cardiomyopathy associated with Friedreich’s ataxia (FA). Administered by the Friedreich’s Ataxia Research Alliance (FARA), it focuses on advancing understanding of cardiac involvement in FA, developing treatments, or pursuing both goals. It sits within FARA’s competitive research program supporting basic research, drug development, and clinical research.
Relevant cardiac priorities include mechanisms and metabolic pathways affecting heart health, comparisons with other cardiomyopathies, biomarkers predicting cardiac outcomes or supporting risk stratification, and therapies to reduce cardiac morbidity and mortality. Research may assess established cardiac treatments for application to FA. All proposed work must address FARA’s research priorities.